Vanguard Capital Management
ACET icon

Vanguard Capital Management’s Adicet Bio ACET Stock Holding History

Vanguard Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Buy
343,228
+6,704
+2% +$52.8K ﹤0.01% 3295
2026
Q1 		$2.29M Buy
+336,524
New +$2.52M ﹤0.01% 3316

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $214M AUM 88.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vanguard Capital Management's ACET Position: Q2 2026 in Review

Vanguard Capital Management increased its Adicet Bio (ACET) stake by 2% in Q2 2026, buying an estimated $52.8K and bringing the position to 343,228 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3295.

Vanguard Capital Management first reported a position in ACET in Q1 2026 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Vanguard Capital Management held 343,228 shares of Adicet Bio worth $2.97M as of Q2 2026.
  • Vanguard Capital Management bought 6,704 Adicet Bio shares in Q2 2026, an estimated $52.8K.
  • Adicet Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3295 holding.
  • Vanguard Capital Management first reported a position in Adicet Bio in Q1 2026 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.